RKDA Arcadia Biosciences Inc

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2024

 

 

Arcadia Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-37383	81-0571538
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5950 Sherry Lane Suite 215
Dallas, Texas				75225
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 214 974-8921

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common		RKDA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

Item 7.01 Regulation FD Disclosure.

On December 5, 2024, Arcadia Biosciences, Inc. (the “Company” or “Arcadia”) issued a press release announcing that it had entered into a Securities Exchange Agreement (the “Exchange Agreement”) with Roosevelt Resources, LP, a Texas limited partnership (“Roosevelt” or the “Partnership”), providing for a proposed business combination transaction (the “Transaction”) between the two companies in an all-stock transaction. Arcadia and Roosevelt held a live webcast presentation at 1:30 p.m. Eastern time on December 11, 2024, to discuss the proposed Transaction.

Furnished as Exhibit 99.1 hereto and incorporated herein by reference is an investor presentation that was discussed during the webcast presentation and will be used by Arcadia and Roosevelt in connection with the proposed Transaction. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act’), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. Arcadia makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.

Cautionary Statement Regarding Forward-Looking Information

This Current Report on Form 8-K (the “Report”) contains forward-looking statements within the meaning of the safe harbor provided by Section 27A of the Securities Act, Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, about Arcadia and Roosevelt. Forward-looking statements are all statements other than statements of historical facts. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “guidance,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely” “plan,” “positioned,” “strategy,” and similar expressions or other words of similar meaning, and the negatives thereof, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, any statements regarding the expected timetable for completing the proposed Transaction pursuant to the Exchange Agreement, the results, effects, and benefits of the proposed Transaction, future opportunities for the combined company, and future financial performance and condition of the combined company. Any other statements regarding Arcadia’s or Roosevelt’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are forward-looking statements. Forward-looking statements involve a wide variety of risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties relating to Arcadia include, but are not limited to: the risks set forth in filings that Arcadia makes with the Securities and Exchange Commission (“SEC”) from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2023 and other filings that Arcadia has made with the SEC since that date. Specific forward-looking statements also include, without limitation, statements regarding Roosevelt’s technology, Roosevelt’s anticipated development and production plans, and the ability of Roosevelt to grow production. The risks and uncertainties relating to Roosevelt include, without limitation, statements with respect to Roosevelt’s strategy and prospects; statements about resource potential, expected future expenditures, production, financial position, business strategy, revenues, costs, future oil and gas prices, capital expenditures and debt levels. Forward-looking statements are based on current expectations and assumptions and analyses made by Roosevelt and its management in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors deemed appropriate under the circumstances. However, whether actual results and developments will conform to expectations is subject to a number of material risks and uncertainties, including but not limited to: declines in oil, natural gas liquids or natural gas prices; the level of success in development and production activities; adverse weather conditions that may negatively impact development or production activities; the timing of development expenditures; inaccuracies of reserve estimates or assumptions underlying them; revisions to reserve estimates as a result of changes in commodity prices; risks related to level of indebtedness and periodic redeterminations of the borrowing base and interest rates under Roosevelt’s credit facility; Roosevelt’s ability to generate sufficient cash flows from operations to meet the internally funded portions of its capital expenditures budget; the effects of future regulatory or legislative actions; cost and availability of transportation and storage capacity as a result of oversupply, government regulation or other factors; and possible changes in taxation and environmental regulation.

In addition, these forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to: the possibility that stockholders of Arcadia may not approve the issuance of new shares of Arcadia common stock in the Transaction or other proposals that are a condition to the Transaction or that the stockholders of Arcadia and the partners of Roosevelt may not approve matters relating to the Exchange Agreement; the risk that any condition to closing of the proposed Transaction may not be satisfied, that either party may terminate the Exchange Agreement or that the closing of the proposed Transaction might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Transaction; the diversion of management time on Transaction-related issues; the ultimate timing, outcome and results of integrating the operations of Arcadia and Roosevelt; the effects of the Transaction, including the combined company’s future financial condition, results of operations, strategy and plans; changes in capital markets and the ability of the combined company to finance operations in the manner expected; the risks of oil and gas activities; and the fact that operating costs and business disruption may be greater than expected following the public announcement or consummation of the proposed Transaction. Expectations regarding business outlook, including changes in revenue,

---

pricing, capital expenditures, cash flow generation, strategies for the combined company’s operations, oil and natural gas market conditions, legal, economic and regulatory conditions, and environmental matters are only forecasts regarding these matters.

All forward-looking statements speak only as of the date they are made and are based on information available at that time. Neither Arcadia nor Roosevelt assumes any obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements.

No Offer or Solicitation

This Report, including the information contained herein and the exhibits filed or furnished herewith, is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed Transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom.

Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, any offer of securities will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS REVIEWED, APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS REPORT IS TRUTHFUL OR COMPLETE.

Additional Information about the Transaction and Where to Find It

In connection with the proposed Transaction, Arcadia intends to file a Registration Statement on Form S-4 (the “Registration Statement”) that will include a proxy statement of Arcadia that also constitutes a prospectus of Arcadia common stock to be offered in the proposed Transaction. After the Registration Statement is declared effective by the SEC, Arcadia intends to mail a definitive proxy statement/prospectus to the stockholders of Arcadia. Arcadia may also file other relevant documents with the SEC regarding the proposed Transaction. This Report is not a substitute for the proxy statement/prospectus or the Registration Statement or for any other document that Arcadia may file with the SEC and make available to Arcadia’s stockholders in connection with the proposed Transaction. INVESTORS AND SECURITY HOLDERS OF ARCADIA ARE URGED TO CAREFULLY AND THOROUGHLY READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY ARCADIA WITH THE SEC, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCADIA, ROOSEVELT, THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND RELATED MATTERS.

Investors will be able to obtain free copies of the Registration Statement and proxy statement/prospectus, as each may be amended from time to time, and other relevant documents filed by Arcadia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Arcadia will be available free of charge from Arcadia’s website at www.arcadiabiosciences.com under the “Investors” tab. Investors may also direct a request to Corporate Secretary, Arcadia Biosciences, Inc., 5950 Sherry Lane, Suite 215, Dallas, Texas 75225, Telephone No.: (214) 974-8921. In addition, investors and stockholders should note that Arcadia communicates with investors and the public using its website (www.arcadiobiosciences.com) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Arcadia with the SEC. Stockholders and investors are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Transaction.

Participants in the Solicitation

Arcadia, Roosevelt and their respective directors, partners and certain of their officers and other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from Arcadia’s stockholders in connection with the proposed Transaction. Information regarding the officers and directors of Arcadia is included in Arcadia’s most recent Annual Report on Form 10-K/A filed with the SEC on April 29, 2024, including any information incorporated therein by reference, as filed with the SEC, and its definitive proxy statement for its 2024 annual meeting of stockholders filed with the SEC on May 16, 2024. Additional information regarding such persons, as well as information regarding Roosevelt’s directors, managers and officers and other persons who may be deemed participants in the proposed Transaction, will be set forth in the Registration Statement and proxy statement/prospectus and other materials when they are filed with the SEC in connection with the proposed Transaction. Free copies of these documents may be obtained as described in the paragraphs above.

---

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Investor Presentation dated December 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ARCADIA BIOSCIENCES, INC.
Date:	December 11, 2024	By:	/s/ Mark Kawakami
			Mark Kawakami, Chief Financial Officer

 

---

Arcadia Biosciences & Roosevelt Resources Business CombinationDecember 2024 Filed by Arcadia Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Arcadia Biosciences, Inc. Commission File No.: 001-37383

---

DISCLAIMERForward Looking Statements This Presentation contains forward-looking statements within the meaning of the safe harbor provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, about Arcadia Bioscience, Inc. (“Arcadia”) or Roosevelt Resources, LP (“Roosevelt”). Forward-looking statements are all statements other than statements of historical facts. The words “anticipate,” “believe,” “ensure,” “expect,” “if,” “intend,” “estimate,” “probable,” “project,” “forecasts,” “predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,” “potential,” “may,” “might,” “anticipate,” “likely” “plan,” “positioned,” “strategy,” and similar expressions or other words of similar meaning, and the negatives thereof, are intended to identify forward-looking statements. Forward-looking statements include, without limitation: any statements regarding the expected timetable for completing the proposed Transaction; the results, effects, and benefits of the proposed Transaction; future opportunities for the combined company; future financial performance and condition; and guidance. Any other statements regarding Arcadia’s or Roosevelt’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are forward-looking statements. Forward-looking statements involve a wide variety of risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties relating to Arcadia include, but are not limited to, the risks set forth in filings that Arcadia makes with the Securities and Exchange Commission (“SEC”) from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2023 and other filings that Arcadia has made with the SEC since that date. Specific forward-looking statements also include, without limitation, statements regarding Roosevelt’s technology, Roosevelt’s anticipated development and production plans, and the ability of Roosevelt to grow production. The risks and uncertainties relating to Roosevelt include, without limitation, statements with respect to Roosevelt’s strategy and prospects; statements about resource potential, expected future expenditures, production, financial position, business strategy, revenues, costs, future oil and gas prices, capital expenditures and debt levels. Forward-looking statements are based on current expectations and assumptions and analyses made by Roosevelt and its management in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors deemed appropriate under the circumstances. However, whether actual results and developments will conform to expectations is subject to a number of material risks and uncertainties, including but not limited to: declines in oil, natural gas liquids or natural gas prices; the level of success in development and production activities; adverse weather conditions that may negatively impact development or production activities; the timing of development expenditures; inaccuracies of reserve estimates or assumptions underlying them; revisions to reserve estimates as a result of changes in commodity prices; risks related to level of indebtedness and periodic redeterminations of the borrowing base and interest rates under Roosevelt’s credit facility; Roosevelt’s ability to generate sufficient cash flows from operations to meet the internally funded portions of its capital expenditures budget; the effects of future regulatory or legislative actions; cost and availability of transportation and storage capacity as a result of oversupply, government regulation or other factors; and possible changes in taxation and environmental regulation. In addition, these forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to: the possibility that stockholders of Arcadia may not approve the issuance of new shares of Arcadia common stock in the Transaction or other proposals that are a condition to the Transaction or that the stockholders of Arcadia and the partners of Roosevelt may not approve matters relating to the exchange agreement; the risk that any condition to closing of the proposed Transaction may not be satisfied, that either party may terminate the exchange agreement or that the closing of the proposed Transaction might be delayed or not occur at all; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Transaction; the diversion of management time on Transaction-related issues; the ultimate timing, outcome and results of integrating the operations of Arcadia and Roosevelt; the effects of the business combination of 2

---

DISCLAIMERForward Looking Statements Arcadia and Roosevelt, including the combined company’s future financial condition, results of operations, strategy and plans; changes in capital markets and the ability of the combined company to finance operations in the manner expected; the risks of oil and gas activities; and the fact that operating costs and business disruption may be greater than expected following the public announcement or consummation of the proposed Transaction. Expectations regarding business outlook, including changes in revenue, pricing, capital expenditures, cash flow generation, strategies for our operations, oil and natural gas market conditions, legal, economic and regulatory conditions, and environmental matters are only forecasts regarding these matters. All forward-looking statements speak only as of the date they are made and are based on information available at that time. Neither Arcadia nor Roosevelt assumes any obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. This Presentation may contain hyperlinks to information that is not deemed to be incorporated by reference into this Presentation. No Offer or Solicitation This Presentation, including the information contained herein, is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed Transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, any offer of securities will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS REVIEWED, APPROVED OR DISAPPROVED OF THE SECURITIES TO BE OFFERED BY ARCADIA OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE. Additional Information About the Transaction and Where to Find It In connection with the proposed Transaction, Arcadia intends to file materials with the SEC, including a Registration Statement on Form S-4 (the “Registration Statement”) that will include a proxy statement/prospectus. After the Registration Statement is declared effective by the SEC, Arcadia intends to mail a definitive proxy statement/prospectus to the stockholders of Arcadia. This Presentation is not a substitute for the proxy statement/prospectus or the Registration Statement or for any other document that Arcadia may file with the SEC and make available to Arcadia’s stockholders in connection with the proposed Transaction. 3

---

DISCLAIMERForward Looking Statements INVESTORS AND SECURITY HOLDERS OF ARCADIA ARE URGED TO CAREFULLY AND THOROUGHLY READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY ARCADIA WITH THE SEC, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCADIA, ROOSEVELT, THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND RELATED MATTERS. Investors will be able to obtain free copies of the Registration Statement and proxy statement/prospectus, as each may be amended from time to time, and other relevant documents filed by Arcadia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Arcadia will be available free of charge from Arcadia’s website at www.arcadiabiosciences.com under the “Investors” tab. In addition, investors and stockholders should note that Arcadia communicates with investors and the public using its website (www.arcadiabio.com) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by Arcadia with the SEC. Stockholders and investors are urged to read the proxy statement/ prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed Transaction. Participants in the Proxy Solicitation Arcadia, Roosevelt and their respective directors, partners and certain of their officers and other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from Arcadia’s stockholders in connection with the proposed Transaction. Information regarding the officers and directors of Arcadia is included in Arcadia’s most recent Annual Report on Form 10-K/A filed with the SEC on April 29, 2024, including any information incorporated therein by reference, as filed with the SEC, and its definitive proxy statement for its 2024 annual meeting filed with the SEC on May 16, 2024. Additional information regarding such persons, as well as information regarding Roosevelt’s directors, managers and officers and other persons who may be deemed participants in the proposed transaction, will be set forth in the Registration Statement and proxy statement/prospectus and other materials when they are filed with the SEC in connection with the proposed transaction. Free copies of these documents may be obtained as described in the paragraphs above. Industry and Market Data Certain information contained in this Presentation relates to or is based on studies, publications, surveys or Roosevelt’s own internal estimate and research. In this Presentation, Arcadia and Roosevelt rely on, and refer to, publicly available information and statistics regarding the sector in which Roosevelt competes and other industry data. All of the market data included in this Presentation involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Trademarks This Presentation may contain references to Arcadia or Roosevelt trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, trademarks, service marks, trade names and copyrights referred to in this Presentation, including logos, artwork, and other visual displays, may appear without the ®, TM, SM, ©, or other symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trademarks, service marks, trade names or copyrights to imply a relationship with, or endorsement or sponsorship of us by, any other company. 4

---

Transaction overview 5 * Subject to adjustment Roosevelt equity owners will own ~90% of Arcadia’s pro forma outstanding shares. Arcadia shareholders will own ~10% of Arcadia’s pro forma outstanding shares. Arcadia Biosciences, and Roosevelt Resources have entered into a definitive securities exchange agreement in an all-stock transaction - issuing 12,284,475 shares* of Arcadia common stock to Roosevelt’s partners in exchange for 100% equity interests in Roosevelt. SUMMARY OWNERSHIP* The company will change its name to Roosevelt Resources, Inc. and trade under a new Nasdaq symbol. The board of directors and senior management will be reorganized. The transaction is expected to close during the first quarter of 2025, or thereafter. COMPANY ORGANIZATION TIMELINE HIGHLIGHTS OF AGREEMENT

---

Arcadia’s strategic review led to conclusion that business combination was best alternative for shareholders Conducted extensive evaluation of potential transactions with external advisors Discontinued CBD body care brands in Q3 2023 Monetized Resistant Starch Durum Wheat trait in Q2 2024 Sold GoodWheatTM brand of wheat products in Q2 2024 Expanded focus on Zola® coconut water, growing brand significantly Significantly reduced our use of cash Initiated comprehensive strategic review July 2023 Business combination with Roosevelt Resources announced December 5, 2024 KEY DEVELOPMENTS IN STRATEGIC REVIEW

---

Zola® coconut water sales are strong andoperations will continue 7 Source: NielsenIQ ZOLA in Total Grocery Stores for Latest 13 Weeks Ending 09/28/2024 in shelf stable coconut water Zola revenues grew +55% Y/Y in Q3 2024 and +29% Y/Y on a YTD basis. Growth is primarily driven by a +68% increase in retail distribution in 2024. Retail distribution growth expected to be +80% in 2024. Select Arcadia team members may continue to manage on-going operations of Zola. ZOLA COCONUT WATER HIGHLIGHTS ZOLA GROWTH VS. COCONUT WATER CATEGORY ZOLA PRODUCT PORTFOLIO

---

COMPANY WILL CHANGE NAME NEW OWNERSHIP STRUCTURE POST TRANSACTION MANAGEMENT POST TRANSACTION BOARD OF DIRECTORS Arcadia Biosciences will combine with Roosevelt Resources through the issuance of ~12.3M shares of common stock Arcadia Biosciences, Inc. Roosevelt Resources, LP Roosevelt Resources, Inc. Roosevelt Stakeholders Arcadia Stakeholders Jimmy Hawkins President and Chief Operating Officer Jerrel Branson Chief Financial Officer Tony Roosevelt Chief Executive Officer ARCADIA INDEPENDENT ROOSEVELT

---

File S-4 with Securities & Exchange Commission Schedule special meeting of Arcadia stockholders Mail proxy statement to Arcadia shareholders Special shareholders meeting to vote on transaction Closing Next steps: Transaction is expected to close in Q1 2025 or soon thereafter 9 1 2 3 4 5 TRANSACTION TIMELINE

---

Arcadia Biosciences & Roosevelt Resources Business CombinationDecember 2024

---

Management Team Tony Roosevelt Jr. Chief Executive Officer and Chairman of the Board Jimmy C. Hawkins President and Chief Operating Officer Jerrel Branson Chief Development and Financial Officer Paul Buckner Chief Legal Officer and Corporate Secretary A 64-year veteran of the oil and gas industry, Tony has had a career marked by diversity and success. Starting in the 1960’s he founded General Petroleum Corp., Texas Interstate Oil & Gas Co., followed by General Gas Co. and Caledonia Energy Partners. These operations included domestic and international activities and each were characterized by significant growth and value creation. Tony’s ongoing focus lies in developing the Company’s RR-Googins Field. Jimmy began his career in the U.S. in 1985 as a reservoir engineer for Santa Fe Minerals. He then joined the Kuwait Oil Company, working on projects in 18 countries while leading the long-range planning team. In the 1990s, he created a Field Development Plan for Malaysia CAA PM3 and managed the first phase, recovering over 500 Million BOE. In the early 2000s, he joined Tony Roosevelt to develop the Company’s RR-Googins Field. Jimmy pioneered innovative extraction techniques and designed horizontal wells for CO2 EOR. He holds a BSc in Petroleum Engineering from Texas A&M University in 1984. After a decade of project development financing for First City-Houston in Singapore from 1975 to 1977, Jerrel opened the petroleum consultant office of McCord-Lewis, retained by the governments of Thailand, Malaysia, Indonesia, and the PRC for engineering studies. In 1984 he co-founded VAALCO Energy, which developed a giant oilfield in the Eastern Hemisphere. He later commercially developed some of his patents, focusing on CO2 recovery from industrial sources. In 2022, he joined Roosevelt Resources, bringing his major project development background. He graduated from Rice University in 1972. Paul joined Roosevelt Resources as in-house counsel and Chief Administrative Officer in 2020 following 15 years’ experience as General Counsel and VP- Human Resources of a family-owned oil and gas company. For 12 years prior to joining that company, Paul was in private law practice. He holds degrees from the University of Texas-Austin (1989)and St. Mary’s University School of Law (1992).

---

Northwest Shelf San Andres Fields & CO2 Floods Source: Map: TX Bureau of Economic Geology & NM Bureau of Geology and Mineral Resources. Production estimates by Advanced Resources International (“ARI”) dated 2022. NM TX Oil fields producing From NW Shelf San Andres Platform Carbonate Play Denver Unit ~ 500 gross mmbo from CO2 EOR Seminole Unit ~ 300 gross mmbo from CO2 EOR Vacuum Unit ~ 400 gross mmbo from CO2 EOR Slaughter, Sundown, Mallet > 300 gross mmbo from CO2 EOR SEMINOLE VACUUM Roosevelt Resources Acreage ADAIR Existing CO2 Flood

---

RR Investments to Date $27.1M $75.6M $82.5M 2007-2018 2019-2023 2023-Current EXPLORATION PHASE APPRAISAL PHASE DEVELOPMENT PHASE Geological & Geophysical Studies Three Exploratory H2 Wells Core Extraction Comprehensive Logging 3D Seismic Further Lease Acquisition Reservoir Assessment & Studies Nine Horizontal Appraisal Wells Processing, Roads, Power Infrastructure Fresh Water Acquisition Lease Expansion Reservoir Studies Field Development Plan Upper Reservoir Production Optimization Plan CO2 Sourcing for EOR +$27.1M +$48.5M +$6.9M 1 - Expenditures exclude all back-office overhead, expenditures through mid 2024.

---

CCUS EOR Project Contemplated by In-House and Third-Party Resource Studies1 Aug 2007 Feb 2008 July 2010 Mar 2012 Sept 2012 Oct 2012 April 2023 Feb 2024 Aug 2024 OIP: 71,000 boe/acre OIP: 71,000 boe/acre OIP: 77,000 boe/acre OIP:77,000 boe/acre OIP: 74,220 boe/acre OIP: 74,220 boe/acre (3D seismic) OIP: 84,000 boe/acre OIP: 68,000 boe/acre (3D seismic) OIP: 84,000 boe/acre; EUR: 835 mmbo + 122 mmb NGLs Total OIP (gross bbls) in millions BBL per Acre (gross bo/acre OIP) 1. Oil in place (“OIP”) indicates a resource in the reservoir. Actual oil recoverable is significantly less than OIP. All numbers are gross using 16,208 gross acres of the project and the studies were averaged to the acreage. Estimates of EURs are also dependent on many factors, including the costs of development and operations, capital expenditures to be made and timing thereof and actual prices received for oil and natural gas. Estimates of produceable and recoverable hydrocarbons are not estimates of reserves prepared in accordance with SEC regulations. 2. Included a broader area in which the RR project area was a part.

---

Roosevelt Resources Dataset 25 Section RR EOR CCUS Project, Yoakum County, Texas RR Horizontal Wells Core Data Logs for OIP Assessment Logs for Mapping Calibration 3D Seismic Coverage Cutting images Roosevelt Resources 25 Section CCUS EOR Project Yoakum County, Texas

---

RR Googins EOR Project Phase 1 Calibration Top View Side View

---

CCUS EOR Project using Miscible-Ascending Dispersion (“MAD”) Anticipated production timing(1) 1. Will be heavily dependent on capital expenditures and timing thereof as well as CO2 availability and prices actually received for oil and gas.

---

CO2 Injector Producer SIDE VIEW Reservoir is ~300 ft thick ~250 ft from Injector to Producer Impermeable Seal Impermeable Seal Producer Flowing Bottom Hole Pressure Slightly Above Miscibility (est ~ 1300 psi) Injector CO2 Injection Pressure Slightly Below Pre-frac pressure point (est. ~ 3,300 – 3,500 psi) CO2 moves upward by differential pressure & buoyancy CO2 is laterally dispersed by Earth’s natural layering Higher Permeability Lower Permeability Schlumberger Compositional Reservoir Modeling Estimates Recovery Factor ~ 55% - 60% of the Oil in Place We believe that utilizing Earth’s natural layering to spread dispersion, combined with the use of injectors for horizontal wells, will improve CO2 contact with oil in place. Miscible Ascending Dispersion (MAD)EOR a Better Way in our horizontal wells 18

---

Conclusion Significant Opportunity in Safe Operating Environment Science–CO2 EOR is proven technology in San Andres Development will be accomplished in phases as development occurs Unitization is in process Project has been significantly De-risked – San Andres oil in many other nearby CO2 EOR projects that have produced over 1 billion boe is well-established Project Expansion Options – we believe our EOR technique should be applicable to adjacent and other known locations

v3.24.3

Document And Entity Information	Dec. 11, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 11, 2024
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Emerging Growth Company	false
Entity File Number	001-37383
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	5950 Sherry Lane
Entity Address, Address Line Two	Suite 215
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75225
City Area Code	214
Local Phone Number	974-8921
Written Communications	true
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common
Trading Symbol	RKDA
Security Exchange Name	NASDAQ

---